vs

Side-by-side financial comparison of Core Laboratories Inc. (CLB) and Ibotta, Inc. (IBTA). Click either name above to swap in a different company.

Core Laboratories Inc. is the larger business by last-quarter revenue ($121.8M vs $88.5M, roughly 1.4× Ibotta, Inc.). On growth, Core Laboratories Inc. posted the faster year-over-year revenue change (-1.4% vs -10.0%). Ibotta, Inc. produced more free cash flow last quarter ($20.3M vs $517.0K). Over the past eight quarters, Ibotta, Inc.'s revenue compounded faster (3.7% CAGR vs -3.4%).

Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices.

Ibotta, Inc. is an American mobile technology company headquartered in Denver, Colorado. Founded in 2011, the company offers cash back rewards on various purchases through its Ibotta Performance Network and direct to consumer app. Ibotta partners with CPG brands and network publishers to provide these rewards. As of 2024, the company operates solely in the United States. The company's rewards-as-a-service offering, the Ibotta Performance Network, went live in 2022.

CLB vs IBTA — Head-to-Head

Bigger by revenue
CLB
CLB
1.4× larger
CLB
$121.8M
$88.5M
IBTA
Growing faster (revenue YoY)
CLB
CLB
+8.6% gap
CLB
-1.4%
-10.0%
IBTA
More free cash flow
IBTA
IBTA
$19.8M more FCF
IBTA
$20.3M
$517.0K
CLB
Faster 2-yr revenue CAGR
IBTA
IBTA
Annualised
IBTA
3.7%
-3.4%
CLB

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CLB
CLB
IBTA
IBTA
Revenue
$121.8M
$88.5M
Net Profit
$5.1M
Gross Margin
78.7%
Operating Margin
1.5%
-1.9%
Net Margin
4.2%
Revenue YoY
-1.4%
-10.0%
Net Profit YoY
EPS (diluted)
$0.11
$-0.03

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLB
CLB
IBTA
IBTA
Q1 26
$121.8M
Q4 25
$138.3M
$88.5M
Q3 25
$134.5M
$83.3M
Q2 25
$130.2M
$86.0M
Q1 25
$123.6M
$84.6M
Q4 24
$129.2M
$98.4M
Q3 24
$134.4M
$98.6M
Q2 24
$130.6M
$87.9M
Net Profit
CLB
CLB
IBTA
IBTA
Q1 26
$5.1M
Q4 25
$4.9M
Q3 25
$14.2M
$1.5M
Q2 25
$10.6M
$2.5M
Q1 25
$-154.0K
$555.0K
Q4 24
$7.4M
Q3 24
$11.7M
$17.2M
Q2 24
$9.0M
$-34.0M
Gross Margin
CLB
CLB
IBTA
IBTA
Q1 26
Q4 25
20.8%
78.7%
Q3 25
22.0%
79.4%
Q2 25
20.3%
79.2%
Q1 25
19.5%
79.8%
Q4 24
17.8%
84.6%
Q3 24
20.5%
87.7%
Q2 24
21.2%
86.0%
Operating Margin
CLB
CLB
IBTA
IBTA
Q1 26
1.5%
Q4 25
11.5%
-1.9%
Q3 25
15.6%
2.8%
Q2 25
11.7%
1.4%
Q1 25
3.6%
-3.3%
Q4 24
11.0%
13.2%
Q3 24
14.7%
21.0%
Q2 24
12.3%
-24.6%
Net Margin
CLB
CLB
IBTA
IBTA
Q1 26
4.2%
Q4 25
3.6%
Q3 25
10.6%
1.8%
Q2 25
8.2%
2.9%
Q1 25
-0.1%
0.7%
Q4 24
5.7%
Q3 24
8.7%
17.5%
Q2 24
6.9%
-38.6%
EPS (diluted)
CLB
CLB
IBTA
IBTA
Q1 26
$0.11
Q4 25
$0.11
$-0.03
Q3 25
$0.30
$0.05
Q2 25
$0.22
$0.08
Q1 25
$0.00
$0.02
Q4 24
$0.15
$3.04
Q3 24
$0.25
$0.51
Q2 24
$0.19
$-1.32

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLB
CLB
IBTA
IBTA
Cash + ST InvestmentsLiquidity on hand
$22.8M
$186.6M
Total DebtLower is stronger
$0
Stockholders' EquityBook value
$275.1M
$287.7M
Total Assets
$587.7M
$525.9M
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLB
CLB
IBTA
IBTA
Q1 26
$22.8M
Q4 25
$22.7M
$186.6M
Q3 25
$25.6M
$223.3M
Q2 25
$31.2M
$250.5M
Q1 25
$22.1M
$297.1M
Q4 24
$19.2M
$349.3M
Q3 24
$21.5M
$341.3M
Q2 24
$17.7M
$317.9M
Total Debt
CLB
CLB
IBTA
IBTA
Q1 26
Q4 25
$110.3M
$0
Q3 25
$114.1M
Q2 25
$124.6M
Q1 25
$124.4M
Q4 24
$126.1M
$0
Q3 24
$139.9M
$0
Q2 24
$147.6M
$0
Stockholders' Equity
CLB
CLB
IBTA
IBTA
Q1 26
$275.1M
Q4 25
$266.0M
$287.7M
Q3 25
$271.3M
$329.6M
Q2 25
$261.3M
$354.1M
Q1 25
$253.4M
$401.3M
Q4 24
$246.6M
$457.3M
Q3 24
$250.7M
$378.0M
Q2 24
$240.3M
$359.7M
Total Assets
CLB
CLB
IBTA
IBTA
Q1 26
$587.7M
Q4 25
$584.0M
$525.9M
Q3 25
$591.4M
$569.4M
Q2 25
$602.1M
$600.8M
Q1 25
$591.5M
$639.3M
Q4 24
$585.1M
$678.4M
Q3 24
$600.5M
$598.3M
Q2 24
$597.8M
$556.0M
Debt / Equity
CLB
CLB
IBTA
IBTA
Q1 26
Q4 25
0.41×
0.00×
Q3 25
0.42×
Q2 25
0.48×
Q1 25
0.49×
Q4 24
0.51×
0.00×
Q3 24
0.56×
0.00×
Q2 24
0.61×
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLB
CLB
IBTA
IBTA
Operating Cash FlowLast quarter
$4.0M
$27.8M
Free Cash FlowOCF − Capex
$517.0K
$20.3M
FCF MarginFCF / Revenue
0.4%
22.9%
Capex IntensityCapex / Revenue
8.5%
Cash ConversionOCF / Net Profit
0.77×
TTM Free Cash FlowTrailing 4 quarters
$22.5M
$75.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLB
CLB
IBTA
IBTA
Q1 26
$4.0M
Q4 25
$7.9M
$27.8M
Q3 25
$8.5M
$21.8M
Q2 25
$13.9M
$25.9M
Q1 25
$6.7M
$19.9M
Q4 24
$20.6M
$22.0M
Q3 24
$13.1M
$39.5M
Q2 24
$17.1M
$35.0M
Free Cash Flow
CLB
CLB
IBTA
IBTA
Q1 26
$517.0K
Q4 25
$5.0M
$20.3M
Q3 25
$6.5M
$14.5M
Q2 25
$10.4M
$22.2M
Q1 25
$3.9M
$18.0M
Q4 24
$17.4M
$21.8M
Q3 24
$10.4M
$39.2M
Q2 24
$14.3M
$34.8M
FCF Margin
CLB
CLB
IBTA
IBTA
Q1 26
0.4%
Q4 25
3.6%
22.9%
Q3 25
4.8%
17.4%
Q2 25
8.0%
25.8%
Q1 25
3.1%
21.2%
Q4 24
13.4%
22.1%
Q3 24
7.7%
39.8%
Q2 24
10.9%
39.6%
Capex Intensity
CLB
CLB
IBTA
IBTA
Q1 26
Q4 25
2.1%
8.5%
Q3 25
1.5%
8.7%
Q2 25
2.7%
4.2%
Q1 25
2.3%
2.2%
Q4 24
2.5%
0.2%
Q3 24
2.0%
0.3%
Q2 24
2.2%
0.2%
Cash Conversion
CLB
CLB
IBTA
IBTA
Q1 26
0.77×
Q4 25
1.61×
Q3 25
0.60×
14.19×
Q2 25
1.31×
10.38×
Q1 25
35.78×
Q4 24
2.78×
Q3 24
1.12×
2.29×
Q2 24
1.90×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLB
CLB

Segment breakdown not available.

IBTA
IBTA

Redemption Revenue$78.5M89%
Ad Other Revenue$10.0M11%
Breakage$2.1M2%

Related Comparisons